West Roxbury, MA, United States of America

Jie Lin

This inventor holds 13 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Aveo Pharmaceuticals, Inc., Xoma Technology Ltd., Thomson Reuters Global Resources. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jie Lin. Retrieved from https://idiyas.com/inventor/jie-lin-ftmrjcvk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 7)

% Patents Active = 61.5

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 61(Granted Patents)

Location History:

W. Roxbury, MA (US) (2009)
Shoreview, MN (US) (2010)
West Roxbury, MA (US) (2009 - 2015)

Company Filing History:

12 out of 42

Aveo Pharmaceuticals, Inc.

Thomson Reuters Global Resources

patents

4. 1 out of 1

Xoma Technologies, Ltd.

patent

where one patent can have more than one assignee

Years Active: 2009-2015

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9096664 - Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins (2015-08-04),

2. 8580930 - Hepatocyte growth factor (HGF) binding proteins (2013-11-12),

3. 8575318 - Hepatocyte growth factor (HGF) binding proteins (2013-11-05),

4. 8273355 - Hepatocyte growth factor (HGF) binding proteins (2012-09-25),

5. 8268315 - [object Object] (2012-09-18),

6. 7943344 - Hepatocyte growth factor (HGF) binding proteins (2011-05-17),

7. 7935502 - Hepatocyte growth factor (HGF) binding proteins (2011-05-03),

8. 7809695 - Information retrieval systems with duplicate document detection and presentation functions (2010-10-05),

9. 7736861 - Tivozanib response prediction (2010-06-15),

10. 7659378 - Hepatocyte growth factor (HGF) binding antibody (2010-02-09),

11. 7649083 - Hepatocyte growth factor (HGF) binding antibody (2010-01-19),

12. 7615353 - Tivozanib response prediction (2009-11-10),

13. 7556796 - Directed complementation (2009-07-07),

Title: Innovations of Jie Lin in Hepatocyte Growth Factor Research

Introduction

Jie Lin is a prominent inventor based in West Roxbury, MA, with a remarkable portfolio of 13 patents. His work primarily focuses on the development of binding proteins that interact with hepatocyte growth factor (HGF), which has significant implications for therapeutic applications.

Latest Patents

Among his latest patents, Jie Lin has developed a family of nucleic acid encoding hepatocyte growth factor (HGF) binding proteins. These innovative binding proteins are designed to bind and neutralize the activity of HGF, particularly human HGF. The therapeutic potential of these proteins is noteworthy, as they can be utilized to treat various HGF responsive disorders, including certain types of tumors. Additionally, he has patented similar binding proteins that also target HGF, reinforcing their diagnostic and therapeutic capabilities.

Career Highlights

Throughout his career, Jie Lin has made significant contributions to the field of biotechnology. He has worked with notable companies such as Aveo Pharmaceuticals, Inc. and Xoma Technology Ltd., where he has applied his expertise in developing innovative solutions for medical challenges.

Collaborations

Jie Lin has collaborated with esteemed colleagues, including William M Winston, Jr. and S Kirk Wright, further enhancing the impact of his research and innovations in the field.

Conclusion

Jie Lin's contributions to the understanding and application of hepatocyte growth factor binding proteins highlight his role as a leading inventor in biotechnology. His work continues to pave the way for advancements in therapeutic treatments for HGF responsive disorders.

Profile summary based on public USPTO records.